Search

Hepatic associated metabolic disorders represent 5% of the indications for orthotopic liver transplantation (OLTX) according to the European Liver Transplant Registry. We studied the outcome of this group at our institution after OLTX and combined liver/kidney transplantation. Between September 1988 and January 1997, 837 OLTXS were performed in 735 patients. Patient survival and graft function at 1 yr were 91.3 and 86%, respectively. Thirty‐nine OLTXs were performed in 38 patients (15 female/23 male, median age ± SD: 35 14 yr, range 4‐60 yr) due to liver associated metabolic disorders (4.7%). Indications included Wilson's disease (n = 14), α‐1‐anti‐trypsin‐deficiency (n = 7), hemochromatosis (n = 4), erythropoetic protoporphyria (n = 4), cystic fibrosis (n = 2), Crigler‐Najjar syndrome type I (n = 1), glycogenosis type I (n = 1), ornithine‐transcarbomylase‐deficiency (n = 1). In addition 4 patients suffering from primary hyperoxaluria type I received combined liver/kidney grafts. Survival rate the 1 yr after OLTX and combined OLTX/NTX was 91.8%. Twenty patients received cyclosporin A (55%) and 17 patients tacrolimus (45%) as primary immunosuppression. The mean follow‐up was 28.6 months (range 4‐73 months). Two patients with hemochromatosis died 1 and 3 months after OLTX, respectively, from Aspergillus sepsis followed by multiorgan‐failure. One patient died of malignant lymphoma 5 months after transplantation. One patient required retransplantation 2 months after OLTX following arterial thrombosis and ischemic type biliary lesion. One year after OLTX, all patients demonstrated good graft function, liver grafts (ALT 17.9 ± 13.6 IU/L, bilirubin 0.8±0.3.mg/dl, thromboplastin time 94±15%), and combined liver/kidney grafts (creatinine 2.4±1.4 mg/dl). OLTX, respectively combined OLTX/NTX, represent a successful therapy for hepatic associated metabolic disorders. Survival rates and graft function are similar to those in liver graft recipients for established indications at our institution. OLTX seems to be an excellent treatment for hepatic based therapy resistant neurological disorders.